Malignant Melanoma Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The malignant melanoma treatment market size has grown rapidly in recent years. It will grow from $7.21 billion in 2024 to $8.05 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to targeted therapies, patient awareness and education, collaborative research initiatives, regulatory approvals.

The malignant melanoma treatment market size is expected to see rapid growth in the next few years. It will grow to $12.08 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to personalized medicine, global health initiatives, expanded genomic profiling, value-based healthcare models, patient-centric approaches. Major trends in the forecast period include integration of artificial intelligence (AI), early detection technologies, real-world evidence and data analytics, precision medicine integration, combination therapies.

The rising exposure to ultraviolet (UV) radiation is anticipated to drive the growth of the malignant melanoma treatment market in the future. Ultraviolet (UV) radiation is a type of electromagnetic radiation with wavelengths shorter than visible light but longer than X-rays. The development of malignant melanoma is significantly impacted by exposure to UV radiation, particularly UVA (315-400 nm) and UVB (280-315 nm). UV radiation can harm the DNA in skin cells, resulting in mutations that lead to uncontrolled growth and division of these cells, ultimately forming a tumor. For instance, in February 2023, the Melanoma Research Foundation, a U.S.-based organization, reported that the total number of melanoma cases in the United States in 2023 was 187,000, which marked a 7.3% increase to 200,651 in 2024. Additionally, in February 2024, the United States Environmental Protection Agency, a U.S. government agency, stated that skin cancer is the most prevalent cancer in the U.S., with unprotected UV exposure being the primary preventable risk factor, affecting one in five Americans during their lifetime. Consequently, the increasing exposure to ultraviolet (UV) radiation is propelling the growth of the malignant melanoma treatment market.

The rising incidence of melanoma is expected to contribute to the growth of the malignant melanoma treatment market in the future. Melanoma is a type of skin cancer that originates in melanocytes, the skin cells responsible for producing pigment. Treatment for melanoma typically involves the surgical removal of the tumor, and additional therapies, such as immunotherapy or targeted therapy, may be recommended depending on the cancer's stage and extent. For example, in February 2023, the Melanoma Research Foundation, a U.S.-based organization, reported that the total number of melanoma cases in the United States in 2023 was 187,000, which increased by 7.3% to reach 200,651 in 2024. Thus, the increasing incidence of melanoma is driving the growth of the malignant melanoma treatment market.

Prominent players in the malignant melanoma treatment market are strategically focused on the development and approval of innovative drugs to fortify their market position. The increasing demand for more effective and safer treatments has led to a surge in drug approvals for malignant melanoma treatment, exemplified by Opdualag. This novel therapeutic option is a fixed-dose combination featuring two immunotherapy drugs, nivolumab and relatlimab-rmbw, designed to address unresectable or metastatic melanoma. Bristol Myers Squibb, a leading US-based pharmaceutical company, obtained approval for Opdualag from the US Food and Drug Administration in March 2022. Administered as a single intravenous infusion, Opdualag represents a first-in-class treatment, providing a groundbreaking approach for adult and pediatric patients aged 12 or older with metastatic or unresectable melanoma. Relatlimab-rmbw, a human IgG4 monoclonal antibody targeting the LAG-3 receptor, complements nivolumab in this fixed-dose combination. Opdualag's successful launch marks a significant addition to Bristol Myers Squibb's portfolio of cancer treatments, contributing to the company's overall growth.

In June 2022, Germany-based biotechnology firm Immatics N.V. joined forces with Bristol Myers Squibb to pioneer gamma delta allogeneic cell therapy programs. This collaboration is geared towards advancing cutting-edge cancer immunotherapies with the potential to revolutionize the treatment landscape for various cancers, including malignant melanoma. Bristol Myers Squibb, as a US-based pharmaceutical company, remains steadfast in its commitment to discovering, developing, and delivering innovative medicines to patients grappling with serious diseases, with a particular focus on advancing treatments for melanoma. The collaboration with Immatics N.V. underscores the company's dedication to advancing the field of cancer immunotherapy and exploring new avenues for enhanced treatment modalities.

Major companies operating in the malignant melanoma treatment market report are Johnson & Johnson Private Limited, Pfizer Inc., Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Mylan N.V., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, bioMérieux SA, Ono Pharmaceutical Co. Ltd., Exelixis Inc., Array BioPharma Inc., Pierre Fabre Group, Clinigen Group, Iovance Biotherapeutics Inc., X4 Pharmaceuticals Inc., Mirati Therapeutics Inc., Moleculin Biotech Inc., Polynoma LLC, Enzon Pharmaceuticals Inc., Northwest Biotherapeutics Inc.

North America was the largest region in the malignant melanoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant melanoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malignant melanoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The malignant melanoma treatment market consists of revenues earned by entities by providing services such as diagnosis and staging services, surgical services, medical treatments, genetic counseling, aesthetic services, and cosmetic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant melanoma treatment market also includes sales of aldesleukin, binimetinib, braftovi (encorafenib), cobimetinib fumarate, cotellic (cobimetinib fumarate), dabrafenib mesylate, dacarbazine, and encorafenib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Malignant melanoma treatment involves medical interventions and therapies aimed at managing and potentially curing malignant melanoma, a type of skin cancer originating from melanocytes, the cells responsible for producing the skin pigment melanin. The treatment of malignant melanoma provides several critical advantages for the well-being and potential recovery of individuals diagnosed with this aggressive form of skin cancer.

The primary treatments for malignant melanoma include immunotherapy, radiation therapy, chemotherapy, and others. Immunotherapy is a medical treatment that utilizes the body's own immune system to combat diseases, including certain types of cancer. Indicated for treating lentigo malignant melanoma, acral lentiginous melanoma, nodular melanoma, and superficial spreading melanoma, these treatments are administered by various end-users such as hospitals, specialty clinics, and others.

The malignant melanoma treatment market research report is one of a series of new reports that provides malignant melanoma treatment market statistics, including malignant melanoma treatment industry global market size, regional shares, competitors with a malignant melanoma treatment market share, detailed malignant melanoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malignant melanoma treatment industry. This malignant melanoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.